Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 7/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100369 | 0.91 | CAMKK2 (0.60) | CAMKK2MAPK8PIK3CGMAPK10IKBKB | |
| SCHEMBL27576337 | 0.91 | CAMKK2 (0.70) | CAMKK2MAPK8PIK3CGMAPK10IKBKB | |
| SCHEMBL5089555 | 0.87 | CAMKK2 (0.55) | CAMKK2MAPK8PIK3CGMAPK10IKBKB | |
| SCHEMBL5089258 | 0.83 | CAMKK2 (0.68) | CAMKK2MAPK8PIK3CGMAPK10IKBKB | |
| SCHEMBL5989559 | 0.82 | CAMKK2 (0.46) | CAMKK2MAPK8PIK3CGMAPK10IKBKB | |
| SCHEMBL15343081 | 0.80 | CYP1A2 (0.63) | CAMKK2MAPK8GSK3BUSP2CYP1A2 | |
| SCHEMBL5091547 | 0.80 | CAMKK2 (0.53) | CAMKK2MAPK8PIK3CGMAPK10HDAC1 | |
| SCHEMBL5091983 | 0.80 | MAPK8 (0.61) | CAMKK2MAPK8PIK3CGMAPK10IKBKB | |
| SCHEMBL5089243 | 0.80 | MAPK8 (0.56) | CAMKK2MAPK8PIK3CGMAPK10IKBKB | |
| SCHEMBL5089234 | 0.78 | DYRK1A (0.64) | CAMKK2MAPK8PIK3CGMAPK10HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100506801-C | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| CN-1592743-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2005-03-09 | — | — | CN | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| CN-1312807-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2001-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CAMKK2 692/4885MAPK8 878/4885PIK3CG 157/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CAMKK2 707/4885MAPK8 849/4885PIK3CG 143/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CAMKK2 707/4885MAPK8 849/4885PIK3CG 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.